(3-{[4-Aminomethyl-1-(5,6,7,8-tetrahydro-cyclopenta[4,5]pyrrolo[2,3-d]pyrimidin-4-yl)-piperidine-4-carbonyl]-amino}-phenyl)-acetic acid methyl ester

ID: ALA3799932

Chembl Id: CHEMBL3799932

PubChem CID: 127046989

Max Phase: Preclinical

Molecular Formula: C25H30N6O3

Molecular Weight: 462.55

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COC(=O)Cc1cccc(NC(=O)C2(CN)CCN(c3ncnc4[nH]c5c(c34)CCC5)CC2)c1

Standard InChI:  InChI=1S/C25H30N6O3/c1-34-20(32)13-16-4-2-5-17(12-16)29-24(33)25(14-26)8-10-31(11-9-25)23-21-18-6-3-7-19(18)30-22(21)27-15-28-23/h2,4-5,12,15H,3,6-11,13-14,26H2,1H3,(H,29,33)(H,27,28,30)

Standard InChI Key:  DSWZDIKQFDCBGM-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3799932

    ---

Associated Targets(Human)

LIMK2 Tchem LIM domain kinase 2 (949 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (7708 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 462.55Molecular Weight (Monoisotopic): 462.2379AlogP: 2.35#Rotatable Bonds: 6
Polar Surface Area: 126.23Molecular Species: BASEHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 13.68CX Basic pKa: 9.16CX LogP: 2.45CX LogD: 0.68
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.48Np Likeness Score: -0.88

References

1. Alen J, Bourin A, Boland S, Geraets J, Schroeders P, Defert O.  (2016)  Tetrahydro-pyrimido-indoles as selective LIMK inhibitors: synthesis, selectivity profiling and structureactivity studies,  (3): [10.1039/C5MD00473J]
2. Manetti F..  (2018)  Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.,  155  [PMID:29908439] [10.1016/j.ejmech.2018.06.016]

Source